Estrella Immunopharma Inc.
ESLA | NASDAQ
$0.52
-$0.01 (-1.70%)
Sep 21, 2026, 11:09 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -9.79M | -13.25M | -13.06M | -13.5M | -12.08M | -10.48M | -8.85M | -8.82M | -7.31M | -3.53M | -3.21M | -4.95M | -3.62M | -4.53M | -4.55M | -1.9M | -1.46M | -382.3K | -214K | -108.11K | n/a |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 114.31K | 220.1K | 601.99K | 806.3K | 756.17K | 650.38K | 269.35K | 65.6K | 1.43K | 1.43K | 571 | 4 |
Pretax Income | -10.01M | -13.25M | -13.06M | -13.5M | -12.08M | -10.48M | -8.85M | -8.82M | -7.31M | -3.42M | -2.99M | -4.73M | -3.2M | -4.22M | -4.34M | -1.69M | -1.46M | -385.29K | -217K | -111.1K | -3.56K |
Net Income | -10.01M | -13.25M | -13.06M | -13.5M | -12.08M | -10.48M | -8.85M | -8.82M | -7.31M | -3.44M | -3.03M | -4.77M | -3.24M | -4.24M | -4.34M | -1.69M | -1.46M | -385.29K | -217K | -111.1K | -3.56K |
Selling & General & Admin | 2.81M | 3.01M | 2.81M | 3.24M | 3.15M | 2.69M | 2.44M | 2.36M | 3.2M | 2.93M | 2.61M | 1.81M | 701.67K | 578.63K | 442.68K | 326.67K | 296.25K | 263.99K | 282.24K | 249.84K | n/a |
Research & Development | 6.98M | 10.24M | 10.25M | 10.26M | 8.93M | 7.79M | 6.41M | 6.45M | 4.11M | 3.16M | 5.76M | 8.29M | 10.41M | 8.88M | 6.44M | 3.91M | 1.39M | 347.21K | 160.67K | 87.17K | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.56M | -5.15M | -5.15M | -5.15M | -2.59M | n/a | n/a | -228.9K | -228.9K | -228.9K | -228.9K | n/a |
Operating Expenses | 9.79M | 13.25M | 13.06M | 13.5M | 12.08M | 10.48M | 8.85M | 8.82M | 7.31M | 3.53M | 3.21M | 4.95M | 5.96M | 6.87M | 6.88M | 4.23M | 1.46M | 382.3K | 214.01K | 108.11K | n/a |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 7.71M | 13.25M | 13.06M | 13.5M | 12.08M | 10.48M | 8.85M | 8.82M | 7.31M | 3.53M | 3.21M | 4.95M | 5.96M | 6.87M | 6.88M | 4.23M | 1.46M | 382.3K | 214.01K | 108.11K | n/a |
Income Tax Expense | -25 | 825 | 838 | 926 | 926 | 1.7K | 1.69K | 1.63K | 1.63K | 21.08K | 40.54K | 40.54K | 40.54K | 19.47K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 43M | 42.12M | 37.97M | 37.1M | 36.17M | 36.19M | 36.68M | 36.21M | 36.61M | 35.52M | 35.2M | 1.05M | 2.33M | 2.33M | 2.33M | 5.85M | 35.2M | 5.85M | 35.2M | 5.85M | 6.07M |
Shares Outstanding (Diluted) | 43M | 42.12M | 37.97M | 37.1M | 36.17M | 36.19M | 36.68M | 36.21M | 36.61M | 35.52M | 35.2M | 1.05M | 2.33M | 2.33M | 2.33M | 5.85M | 35.2M | 5.85M | 35.2M | 5.85M | 6.07M |
EPS (Basic) | -0.25 | -0.35 | -0.35 | -0.37 | -0.33 | -0.29 | -0.25 | -0.25 | -1.93 | -1.85 | -1.87 | -3.02 | -1.30 | -1.30 | -1.30 | -0.12 | -0.08 | -0.05 | -0.02 | -0.02 | 0 |
EPS (Diluted) | -0.25 | -0.35 | -0.35 | -0.37 | -0.33 | -0.29 | -0.25 | -0.25 | -1.93 | -1.85 | -1.87 | -3.02 | -1.30 | -1.30 | -1.30 | -0.12 | -0.08 | -0.05 | -0.02 | -0.02 | 0 |
EBITDA | -9.79M | -13.25M | -13.06M | -13.5M | -12.08M | -10.48M | -8.85M | -8.69M | -7.15M | -3.25M | -5.52M | -7.38M | -8.43M | -9.38M | -6.76M | -4.05M | -1.27M | -275.48K | -161.19K | -111.1K | -3.56K |
EBIT | -7.71M | -13.25M | -13.06M | -13.5M | -12.08M | -10.48M | -8.85M | -8.82M | -7.31M | -3.42M | -5.69M | -7.42M | -8.44M | -9.46M | -6.88M | -4.23M | -1.46M | -385.29K | -217K | -111.1K | -3.56K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 122.09K | 163.67K | 163.67K | 169.16K | 47.07K | 5.49K | 76.88K | 125.39K | 181.2K | 181.2K | 109.81K | 55.81K | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ESLA